Home » News and events » Press releases

Press releases

Press releases

  • May 21, 2015

    MONTREAL, May 21, 2015 – Alethia Biotherapeutics Inc. announced today the commencement of patient dosing in a Phase 1 clinical trial with AB-16B5, a fully humanized monoclonal antibody that inhibits epithelial to mesenchymal transition (EMT), in patients with advanced solid tumors.

     

  • February 17, 2015

    Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers

    Alethia PR 150217_EN

  • January 20, 2015

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,937,163 entitled “Antibodies against kidney associated antigen 1 and antigen binding fragments thereof” by the United States Patent and Trademark Office (“USPTO”)

  • December 2, 2014

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,900,579 entitled “Siglec-15 antibodies in treating bone loss-related diseases” by the United States Patent and Trademark Office (“USPTO”)

  • August 12, 2014

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,802,826  entitled “Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume” by the United States Patent and Trademark Office (“USPTO”)

  • August 1, 2014

    Alethia Biotherapeutics announces the issuance of patent JP5589149  entitled “Polynucleotides and polypeptide sequences involved in cancer ” by the Japan Patent Office

  • June 20, 2014

    Alethia Biotherapeutics announces the issuance of patent JP5564249 entitled “Polynucleotides and polypeptide sequences involved in cancer ” by the Japan Patent Office

  • June 3, 2014

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,741,289  entitled “Siglec-15 antibodies in treating bone loss-related diseases” by the United States Patent and Trademark Office (“USPTO”)

  • March 5, 2014

    Alethia Biotherapeutics announces the issuance of patent EP2275547 entitled “Polynucleotides and polypeptide sequences involved in the process of bone remodeling ” by the European Patent Office

  • January 20, 2014

    Alethia Biotherapeutics announces publication of data about its bone antiresorptive program published in the Journal of Biological Chemistry: “Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption”.

    http://www.jbc.org/content/289/10/6498.long